A new study published in the journal Thorax has revealed that Swedish clinical air flow technology developer, Airsonett's asthma device, Protexo provides a higher quality of life for asthma patients when compared to placebo.
Protexo is a temperature controlled laminar air-flow device (TLA) , which creates a downward flow of filtered air. This air then surrounds the breathing zone of the sleeping asthma patients and protects them from allergens and irritants.
The study was based on a trial carried out among 281 asthma patients aged between 7 to 70 years and living in six different countries. Around 189 patients slept with Protexo while the remaining patients used a dummy device.
At the end of one year, the researchers found those who used Protexo displayed around 15 percent better quality of life compared to those with the dummy device when key symptoms such as lung capacity, airway inflammation, and biological indicators of a systemic allergic response were compared.